Wegovy patient reviews, trial results, and what the evidence actually shows

What the STEP 1 trial found — and why patients' reviews often echo it

The clearest picture of what patients can expect from Wegovy comes from the STEP 1 trial, which followed 1,961 adults with obesity or overweight and at least one weight-related condition for 68 weeks. Average weight loss on semaglutide 2.4 mg was around 15%, compared with just under 3% on placebo. About a third of participants lost more than 20%. Those are trial-condition figures, and real-world results vary, but the pattern described by UK patients in reviews tends to rhyme: slow progress in the first four weeks, then a more sustained reduction that builds through the escalation phase.

A question our prescribers hear most weeks is whether the reviews they've read online reflect what they should actually expect. The honest answer is: the experiences people share are largely consistent with the clinical data, but the range is wide. Some people lose 5% by week 12; others are approaching 15% by that point. Starting weight, adherence to lifestyle changes, which dose you reach, and individual biology all shift the outcome. The weight-loss results people describe tend to track closely with how far up the dose schedule they've been able to go.

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. If you want to understand whether you might be eligible, our Wegovy patient page explains who the treatment is intended for and what a clinical assessment involves.

The side effects patients mention most, and what the data says about them

Across semaglutide patient reviews in the UK, gastrointestinal symptoms appear in almost every account. Nausea is the most frequently named, followed by constipation, diarrhoea and burping. The NHS medicines page for semaglutide confirms these as the most common side effects, and the STEP 1 trial data backs that up: GI events were reported by the majority of participants on the active dose, though most were mild to moderate and eased within days to a couple of weeks, particularly after the body had adjusted to a new dose level.

What patient accounts add to the clinical picture is texture. Many describe the nausea as worst in the 24 to 48 hours after an injection, improving by the end of the week. Eating smaller meals, staying hydrated and avoiding very fatty foods comes up repeatedly as something that helped. A smaller number of patients in reviews describe more persistent symptoms that led them to slow their dose escalation, which is exactly what the titration schedule is designed to allow. You and your prescriber decide the pace, not a fixed calendar.

On the side-effect experiences patients have shared in more detail, the theme is usually that early discomfort eased, and most people who stuck with the dose adjustment found it manageable. That said, anyone experiencing severe, persistent stomach pain that radiates to the back should seek urgent medical attention, this can be a sign of pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update for GLP-1 medicines. Suspected side effects can be reported at Yellow Card.

What patients say about stopping Wegovy, and what the evidence confirms

One of the most consistent threads in Wegovy patient reviews is what happens when treatment ends. People describe weight returning, sometimes quickly, and express frustration that this aspect wasn't made clear at the outset. The clinical data is unambiguous here: in extension studies following STEP 1, participants who stopped semaglutide regained most of the weight lost within a year. The medicine works while it's taken; it doesn't reprogram the body permanently.

This isn't a criticism of the medicine, it reflects the biology of appetite regulation. Weight regain after stopping a GLP-1 medicine is well-documented, and NICE's recommendation for semaglutide under technology appraisal TA875 includes a maximum treatment duration of two years within specialist NHS services, partly for this reason. Private treatment timelines are discussed with your prescriber and reviewed at each repeat. The key point patients in reviews wish they'd understood earlier: Wegovy is a long-term treatment, not a short course.

For context on what ongoing treatment involves and what it typically costs through a regulated private service, the Wegovy pricing page sets out what's included in a transparent private prescription. There are no subscriptions, and every repeat goes through clinical review. If you're reading reviews and thinking about whether this might be right for you, the starting point is a clinical assessment, not a comparison of anecdotes.

How to read patient reviews of Wegovy critically

Patient reviews of semaglutide are genuinely useful, they describe lived experience in ways clinical trials don't. But they carry selection bias. People who had a strong positive or strongly negative experience are more likely to write about it than those who had a steady, unremarkable course of treatment. That middle group, who lost a meaningful amount of weight with manageable side effects and carried on, is underrepresented online. Reading a broad range of accounts, including the Wegovy reviews collected from verified patients, gives a more balanced picture of what treatment typically looks like.

Reviews from unverified sources also raise a different concern: some sellers of weight-loss injections operate outside the regulated UK supply chain. The MHRA has seized large quantities of fake pens sold through social media and unregistered websites, fake product with no clinical oversight. Any pharmacy supplying Wegovy legally in the UK must be registered on the GPhC register, which you can search at pharmacyregulation.org. A prescription must be issued before any medicine is dispensed. Reviews praising the speed of access from a seller who required no clinical assessment are a red flag, not a recommendation.

If you want to explore what treatment looks like through a regulated service (including how the assessment works and what the process involves) our Wegovy overview covers the full picture, and our clinical team is available to review your consultation the same day it's submitted. When you're ready, you can start your free consultation without any obligation.